A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE.

导出 LinkOut

翻译打印收藏纠错

第一作者： Zicong,Xia

第一单位： Department of Interventional Radiology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001 Jiangsu, China.

作者： Zicong,Xia ^[1] ; Wenjing,Zhao ^[2] ; Jibin,Liu ^[2] ; Jing,Zhang ^[1] ; Jing,Pan ^[1] ; Kang,Chen ^[1] ; Lele,Wang ^[1] ; Hui,Zhao ^[1] ; Xiaoqing,Chen ^[3]

作者单位： Department of Interventional Radiology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001 Jiangsu, China. ^[1] Cancer Research Center Nantong, Tumor Hospital Affiliated to Nantong University, Nantong, 226361 Jiangsu, China. ^[2] Research Center of Clinical Medicine, Talents Office of Party Committee and Human Resources Department, Affiliated Hospital of Nantong University, Nantong, 226001 Jiangsu, China. ^[3]

DOI 10.1155/2022/2704862

PMID 36213835

发布时间 2022-10-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of oncology

2022年2022卷

2704862页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE.

Journal of oncology

相似文献

Journal of oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE.

Journal of oncology

相似文献

Journal of oncology

相关期刊

检索历史清除